Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Type 2 Diabetes Mellitus, T2DM
In brief
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Key facts
- Study ID
- NCT07527650
- Run by
- Hanmi Pharmaceutical Company Limited
- People needed
- 180
- Starts
- 2026-05-18
- Expected to finish
- 2027-10-01
- Last updated by the study team
- 2026-08-03
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Manassas Clinical Research Center — Manassas, Virginia, United States (enrolling)
- Accel Research Sites - DeLand — DeLand, Florida, United States (enrolling)
- Charter Research — Orlando, Florida, United States (enrolling)
- Desert Clinical Research — Mesa, Arizona, United States (enrolling)
- Centricity Research IRT - DBA IACT Health Columbus Piedmont — Columbus, Georgia, United States (enrolling)
- The South Bend Clinic — South Bend, Indiana, United States (enrolling)
- Jefferson City Medical Center — Jefferson City, Missouri, United States (enrolling)
- Clay Platte Family Medicine — Kansas City, Missouri, United States (enrolling)
- Methodist Physicians Clinic — Fremont, Nebraska, United States (enrolling)
- Santa Rosa Medical Centers of Nevada — Las Vegas, Nevada, United States (enrolling)
- Lucas Research, Inc. — Morehead City, North Carolina, United States (enrolling)
- Centricity Research Columbus — Columbus, Ohio, United States (enrolling)
- Olympus Family Medicine — Salt Lake City, Utah, United States (enrolling)
- AdventHealth Translational Research Institute — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.